Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121470 · ClinicalTrials.gov registry record
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
A clinical trial of Acute Kidney Injury, sponsored by BioPorto Diagnostics.
- Completed
- Registry status
- 252
- Enrollment target
- 4
- Study locations
NCT02121470 is a study of Acute Kidney Injury that has completed, run by BioPorto Diagnostics. The registered enrollment target is 252 participants, below the 2,328-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02121470, a study of Acute Kidney Injury, has completed, sponsored by BioPorto Diagnostics.
- COMPLETED
- Registry status
- 252 participants
- Enrollment target
- 4
- Study locations
Study Summary
Acute Kidney Injury (AKI) is a common and severe complication in critically ill patients which is associated with increased morbidity and mortality as well as high costs of medical care. NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, siderocalin) is a biomarker, that is expressed in several tissues including the kidneys. Renal expression of NGAL is dramatically increased in kidney injury from a variety of causes, and NGAL is released into both urine and plasma. NGAL levels rise within two hours of the insult, making NGAL an early and sensitive biomarker of kidney injury, with the potential to assist clinicians in managing patients at risk of kidney injury. This study is designed to validate the assigned NGAL cutoff value by comparing to clinical diagnosis of AKI as determined by current clinical practice in the US. The study sites will enroll consecutive ICU patients. Patients are given standard clinical care and lab-work. Each day, one additional urine and two additional plasma samples will be drawn and frozen. These additional samples are shipped to Sponsor for retrospective NGAL measurements. The duration of each subject´s participation will be until discharge from the ICU, or for a maximum 8 days, whichever comes first. In addition serum creatinine values will continue to be collected manually from the hospital data system for 48 hours after discharge from the ICU. (If subject has been in ICU for 8 or more days, the follow up values are collected while the patient is still in the ICU). 250 subjects will be enrolled in total at the three investigator sites. At least 40 patients must be enrolled at each site. The NGAL value will be matched to the "clinical diagnosis" of acute kidney injury (AKI) as specified by KDIGO® guidelines. The clinical diagnosis will be assigned by a three-person adjudication panel based on the entries in the eCRF by the investigators. Adjudicators are blinded for investigation site, AKI-diagnosis by treating physician
Conditions Studied
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Baystate Medical Center / WNERTA - Springfield
New York
- Montefiore Medical Center - The Bronx
Texas
- Methodist Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02121470
The ClinicalTrials.gov registry entry for NCT02121470 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,328-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (89% lower). The listed sponsor is BioPorto Diagnostics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 0 interventions.
NCT02121470 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT02121470 about?
NCT02121470 is a clinical study titled "NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care". Acute Kidney Injury (AKI) is a common and severe complication in critically ill patients which is associated with increased morbidity and mortality as well as high costs of medical care. NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, siderocalin) is a biomarker, that is expressed in...
What is the current status of trial NCT02121470?
This trial is currently completed. The enrollment target is 252 participants. The study started on 2014-02. Estimated completion is 2015-06.
What conditions does trial NCT02121470 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
Who is sponsoring clinical trial NCT02121470?
This trial is sponsored by BioPorto Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02121470 being conducted?
This trial has 4 study locations across Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.